BlossomHill Therapeutics Q2 Loss Widens
MT newswire2026/09/18 11:42Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
07:42 AM EDT, 09/18/2026 (MT Newswires) -- BlossomHill Therapeutics (BLSM) reported a Q2 loss on Friday of $8.75 per share, widening from a loss of $5.51 a year earlier. One analyst polled by FactSet expected a GAAP loss of $0.77. The company did not report any revenue for the quarter. Cash and cash equivalents for the quarter ended June 30 totaled $95.4 million, which, together with proceeds from its recent IPO, should be sufficient to fund operations into Q2 2028, the company said.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Recon Technology regains Nasdaq compliance with $1 minimum bid price rule
Bitget•2026/09/18 12:30
Gold.com Names Jill Van as CFO
MT newswire•2026/09/18 12:25
